- Oxford Biomedica PLC oxford Biomedica to host webinar showcasing the TetraVectaTM system TranscriptOct 02, 2023
- Half Year 2023 Oxford Biomedica PLC Earnings Call TranscriptSep 20, 2023£2.69 (+11.39%)Earnings
- Full Year 2022 Oxford Biomedica PLC Earnings Call TranscriptApr 25, 2023£4.53 (+0.67%)Earnings
- Oxford Biomedica PLC at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Half Year 2022 Oxford BioMedica PLC Earnings Call TranscriptSep 15, 2022£4.4 (-3.93%)Earnings
- Full Year 2021 Oxford BioMedica PLC Earnings Call TranscriptApr 20, 2022£5.45 (-14.71%)Earnings
- Half Year 2021 Oxford BioMedica PLC Earnings Call TranscriptSep 22, 2021£16.34 (+10.55%)Earnings
- Full Year 2020 Oxford BioMedica PLC Earnings Call TranscriptApr 15, 2021£10.42 (+0.19%)Earnings
- Half Year 2020 Oxford BioMedica PLC Earnings Call TranscriptSep 17, 2020£8.47 (+1.44%)Earnings
- Oxford BioMedica PLC Annual Shareholders Meeting TranscriptJun 23, 2020
- Full Year 2019 Oxford BioMedica PLC Earnings Call TranscriptMay 06, 2020£7.07 (-2.75%)Earnings
- Half Year 2019 Oxford BioMedica PLC Earnings Call TranscriptSep 04, 2019£6.4 (+0.16%)Earnings
- Full Year 2018 Oxford BioMedica PLC Earnings Call TranscriptMar 14, 2019£6.5 (-2.26%)Earnings
Full Year 2022 Oxford Biomedica PLC Earnings Call Transcript
So hello, everyone, and thank you for joining our meeting today, our analyst report meeting -- on the results of 2022. I'm Frank Mathias. I'm the newly appointed Chief Executive Officer of the company. And believe me, it's a great pleasure to meet you today together with our Chief Financial Officer, Stuart Paynter. I believe you are known here.
So just for those who do not know me by now, I'm French, as you can hear from my accent, I'm sure about that. I was born in Paris, and I went to school there and to the university. So I'm pharmacist by education with a PhD in immunology and more than 30 years now of experience in the biopharmaceutical environment in senior positions at different companies throughout the biopharmaceutical industry. As you might know, I come from another renowned CDMO, namely Rentschler Biopharma, where I was CEO for about 7 years.
So also, I have only started 3 weeks ago. To be very precise, 3 weeks, 1.5 days ago. I can already say the following, and this is in line with what I have expected from the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)